Investigation of distribution, transport and uptake of anti-HIV drugs to the central nervous system

Advanced Drug Delivery Reviews

Volumn 39, Issue 1-3, 1999, Pages 5-31

  Sawchuk, Ronald J ^a   Yang, Zheng ^b  

^a UNIVERSITY OF MINNESOTA   (United States)

^b BRISTOL MYERS SQUIBB   (United States)

Author keywords

AIDS; Brain; Dementia; Efflux; Non nucleoside inhibitor; Nucleoside analog; Pharmacokinetics; Protease inhibitor; Transport; Uptake

Indexed keywords

ANTIBIOTICS; BRAIN; ENZYME KINETICS; NEUROLOGY; PHARMACOKINETICS; VIRUSES;

ACQUIRED IMMUNODEFICIENCY SYNDROME (AIDS); HUMAN IMMUNODEFICIENCY VIRUS (HIV);

CONTROLLED DRUG DELIVERY;

ANTI HUMAN IMMUNODEFICIENCY VIRUS AGENT; DIDANOSINE; GLYCOPROTEIN P; LAMIVUDINE; NUCLEOSIDE DERIVATIVE; PRODRUG; PROTEINASE INHIBITOR; RNA DIRECTED DNA POLYMERASE INHIBITOR; STAVUDINE; ZALCITABINE; ZIDOVUDINE;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; ACTIVE TRANSPORT; AIDS RELATED COMPLEX; AREA UNDER THE CURVE; BLOOD BRAIN BARRIER; BLOOD CEREBROSPINAL FLUID BARRIER; CENTRAL NERVOUS SYSTEM; COMPARTMENT MODEL; DEMENTIA; DRUG BLOOD LEVEL; DRUG CEREBROSPINAL FLUID LEVEL; DRUG DELIVERY SYSTEM; DRUG DISTRIBUTION; DRUG PENETRATION; DRUG TRANSPORT; DRUG UPTAKE; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; MOUSE; NONHUMAN; ORAL DRUG ADMINISTRATION; PARTITION COEFFICIENT; PRIORITY JOURNAL; RAT; REVIEW; SPECIES DIFFERENCE; STEADY STATE; SUBCUTANEOUS DRUG ADMINISTRATION;

EID: 0032824907     PISSN: 0169409X     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0169-409X(99)00017-4     Document Type: Article

References (161)

1. Janssen R.S. Epidemiology and neuroepidemiology of human immunodeficiency virus infection. Berger J.R., Levy R.M. AIDS and the Nervous System. 1997;13-37 Lippincott-Raven, Philadelphia.
2. McGuire D., So Y.T. Neurologic dysfunction: overview. Cohen P.T., Sande M.A., Volberding P.A. The AIDS Knowledge Base: a Textbook on HIV Disease from the University of California, San Francisco, and the San Francisco General Hospital. 1994;5.6-1-5.6-2 Little, Brown, Boston.
3. McArthur J.C., Selnes O.A., Glass J.D., Hoover D.R., Bacellar H. HIV dementia: incidence and risk factors. Price R.W., Perry S.W. HIV, AIDS and the Brain. 1994;251-272 Raven, New York.
4. Centers for Disease Control. Revision of the CDC surveillance case definition for acquired immunodeficiency syndrome. MMWR, 36 (1987) 3S-15S.
5. Brew B.J., Rosenblum M., Price R.W. AIDS dementia complex and primary HIV brain infection. J. Neuroimmunol. 20:1988;133-140.
6. Sidtis J.J., Price R.W. Early HIV-1 infection and the AIDS dementia complex. Neurology. 40:1990;323-326.
7. Tross S., Price R.W., Navia B.A., Thaler H.T., Gold J., Hirsch D.A., Sidtis J.J. Neuropsychological characterization of the AIDS dementia complex: a preliminary report. AIDS. 2:1988;81-88.
8. Grant I., Atkinson J.H., Hesselink J.R., et al. Evidence for early central nervous system involvement in the acquired immunodeficiency syndrome (AIDS) and other human immunodeficiency virus (HIV) infections: studies with neuropsychologic testing and magnetic resonance imaging. Ann. Intern. Med. 107:1987;828-836.
9. McArthur J.C., Cohen B.A., Selnes O.A., et al. Low prevalence of neurological and neuropsychological abnormalities in otherwise healthy HIV-1-infected individuals: results from the Multicenter AIDS Cohort Study. Ann. Neurol. 26:1989;601-611.
10. Miller E.N., Selnes O.A., McArthur J.C., et al. Neuropsychological performance in HIV-1-infected homosexual men: the Multicenter AIDS Cohort Study (MACS). Neurology. 40:1990;197-203.
11. Navia B.A., Cho E.S., Petito C.K., Price R.W. The AIDS dementia complex: II. neuropathology. Ann. Neurol. 19:1986;525-535.
12. McArthur J.C. Neurologic manifestation of AIDS. Medicine (Baltimore). 66:1987;407-437.
13. Rothenberg R., Woelfel M., Stoneburner R., Milberg J., Parker R., Truman B. Survival with the acquired immunodeficiency syndrome: experience with 5833 cases in New York City. New Engl. J. Med. 317:1987;1297-1302.
14. Price R.W. Understanding the AIDS dementia complex (ADC): the challenge of HIV and its effects on the central nervous system. Price R.W., Perry S.W. HIV, AIDS and the Brain. 1993;1-45 Raven Press, New York.
15. McArthur J.C., Cohen B.A., Farzedegan H., Cornblath D.R., Selnes O.A., Ostrow D., Johnson R.T., Phair J., Polk B.F. Cerebrospinal fluid abnormalities in homosexual men with and without neuropsychiatric findings. Ann. Neurol. 23:1988;S34-S37.
16. McGuire D., So Y.T. Intracranial disorders. Cohen P.T., Sande M.A., Volberding P.A. The AIDS Knowledge Base: a Textbook on HIV Disease from the University of California, San Francisco, and the San Francisco General Hospital. 1994;5.7-1-5.7-13 Little, Brown, Boston.
17. Price R.W. The cellular basis of central nervous system HIV-1 infection and the AIDS dementia complex: introduction. Price R.W., Sidtis J.J. The Cellular Basis of Central Nervous System HIV-1 Infection and the AIDS Dementia Complex. 1996;1-29 Haworth, New York.
18. Resnick L., Berger J.R., Shapshak P., Tourtellotte W.W. Early penetration of the blood-brain barrier by HIV. Neurology. 38:1988;9-14.
19. Davis L., Hjelle B.L., Miller V.E., et al. Early viral brain invasion in iatrogenic human immunodeficiency virus infection. Neurology. 42:1992;1736-1739.
20. Resnick L., diMarzo-Veronese F., Schupbach J., et al. Intra blood-brain barrier synthesis of HTLV-III-specific IgG in patients with neurological symptoms associated with AIDS and AIDS-related complex. New Engl. J. Med. 313:1985;1498-1504.
21. Lipton S.A. Treating AIDS dementia. Science. 276:1997;1629-1630.
22. Pialoux G., Fournier S., Moulignier A., Poveda J.-D., Clavel F., Dupont B. Central nervous system as a sanctuary for HIV-1 infection despite treatment with zidovudine, lamivudine and indinavir. AIDS. 11:1997;1302-1303.
23. Goldstein G.W., Betz A.L. The blood-brain barrier. Sci. Am. 255:1986;74-83.
24. Pardridge W.M. Brain drug delivery and blood-brain barrier transport. Drug Deliv. 3:1996;99-115.
25. Tsuji A., Teraski T., Takabatake Y., et al. P-glycoprotein as the drug efflux pump in primary cultured bovine brain capillary endothelial cells. Life Sci. 51:1992;1427-1437.
26. Schinkel A.H., Wagenaar E., Mol C.A., vanDeemter L. p-glycoprotein in the blood-brain barrier of mice influences the brain penetration and pharmacological activity of many drugs. J. Clin. Invest. 97:1996;2517-2524.
27. Spector R. Drug transport in the central nervous system: role of carriers. Pharmacology. 40:1990;1-7.
28. Ghersi-Egea J.-F., Finnegan W., Chen J.-L., Fenstermacher J.D. Rapid distribution of intraventricularly administered sucrose into cerebrospinal fluid cisterns via subarachnoid velae in rat. Neuroscience. 75:1996;1271-1288.
29. Audus K.L., Borchardt R.T. Bovine brain microvessel endothelial cell monolayers as a model system for the blood-brain barrier. Ann. N.Y. Acad. Sci. 507:1987;9-18.
30. Seetharaman S., Barrand M.A., Maskell L., Scheper R.J. Multidrug resistance-related transport proteins in isolated human brain microvessels and in cells cultured from these isolates. J. Neurochem. 70:1998;1151-1159.
31. Pardridge W.M. Transport of small molecules through the blood-brain barrier: biology and methodology. Adv. Drug Deliv. Rev. 15:1995;5-36.
32. Dehouck M.-P., Jolliet-Riant P., Bree F., Fruchart J.-C., Cecchelli R., Tillement J.-P. Drug transfer across the blood-brain barrier: correlation between in vitro and in vivo models. J. Neurochem. 58:1992;1790-1797.
33. Goldstein G.W., Betz A.L., Bowman P.D. Use of isolated brain capillaries and cultured endothelial cells to study the blood-brain barrier. Federation Proc. 43:1984;191-195.
34. Deane R., Segal M.B. The transport of sugars across the perfused choroid plexus of the sheep. J. Physiol. Lond. 362:1985;245-260.
35. Oldendorf W.H. Measurement of brain uptake of radiolabeled substances using a tritiated water internal standard. Brain Res. 24:1970;372-376.
36. Takasato Y., Rapoport S.I., Smith Q.R. An in situ brain perfusion technique to study cerebrovascular port in the rat. Am J. Physiol. 247:1984;H484-H493.
37. Thomas S.A., Segal M.B. Identification of a saturable uptake system for deoxyribonucleosides at the blood-brain and blood-cerebrospinal fluid barriers. Brain Res. 741:1996;230-239.
38. Patlak C.S., Fenstermacher J.D. Measurements of dog blood-brain transfer constants by ventriculocisternal perfusion. Am. J. Physiol. 229:1975;877-884.
39. Elmquist W.F., Sawchuk R.J. Application of microdialysis in pharmacokinetic studies. Pharm. Res. 14:1997;267-288.
40. Morgan M.E., Singhal D., Anderson B.D. Quantitative assessment of blood-brain barrier damage during microdialysis. J. Pharmacol. Exp. Ther. 277:1996;1167-1176.
41. Groothuis D.R., Levy R.M. The entry of antiviral and antiretroviral drugs into the central nervous system. J. Neurovirol. 3:1997;387-400.
42. Benveniste H., Huttemeier P.C. Microdialysis-theory and application. Prog. Neurobiol. 33:1990;195-215.
43. Robinson T.E., Camp D.M. The feasibility of repeated microdialysis for within-subject design experiments: studies on the mesostriatal dopamine system. Robinson T.E., Justice J.B. Jr. Microdialysis in Neurosciences. 1991;189-234 Elsevier, Amsterdam.
44. Fontaine M., Wang Q., Yang H., Elmquist W.F. Effect of inerleukin-2 on the blood-brain barrier: an in vivo microdialysis study. Pharm. Res. 12:1995;S406.
45. Yang Z., Brundage R.C., Barbhaiya R.H., Sawchuk R.J. Microdialysis studies of the distribution of stavudine into the central nervous system in the freely-moving rat. Pharm. Res. 14:1997;865-872.
46. Kakee A., Terasaki T., Sugiyama Y. Brain efflux index as a novel method of analyzing efflux transport at the blood-brain barrier. J. Pharmacol. Exp. Ther. 277:1996;1550-1559.
47. Gallo J.M. Delivery of anti-HIV nucleosides to the central nervous system. Adv. Drug Deliv. Rev. 14:1994;199-209.
48. Klecker R.W., Collins J.M., Yarchoan R., Thomas R., Jenkins J.F., Broder S., Myers C.E. Plasma and cerebrospinal fluid pharmacokinetics of 3′-azido-3′-deoxythymidine: a novel pyrimidine analog with potential application for the treatment of patients with AIDS and related diseases. Clin. Pharmacol. Ther. 41:1987;407-412.
49. Burger D.M., Kraaijeveld C.L., Meenhorst P.L., et al. Penetration of zidovudine into the cerebrospinal fluid of patients infected with HIV. AIDS. 7:1993;1581-1587.
50. Balis F.M., Pizzo P.A., Murphy R.F., et al. The pharmacokinetics of zidovudine administered by continuous infusion in children. Ann. Intern. Med. 110:1989;279-285.
51. Rolinski B., Bogner J.R., Sadri I., Wintergerst U., Goebel F.D. Absorption and elimination kinetics of zidovudine in the cerebrospinal fluid in HIV-infected patients. AIDS Res. Hum. Retroviruses. 15:1997;192-197.
52. Tartaglione T.A., Collier A.C., Coombs R.W., et al. Acquired immunodeficiency syndrome. Cerebrospinal fluid findings in patients before and during long-term oral zidovudine therapy. Arch. Neurol. 48:1991;695-699.
53. Larder B.A., Darby G., Richman D.D. HIV with reduced sensitivity to zidovudine (AZT) isolated during prolonged therapy. Science. 243:1989;1731-1734.
54. Doshi K.J., Gallo J.M., Boudinot F.D., Schinazi R.F., Chu C.K. Comparative pharmacokinetics of 3′-azido-3′-deoxythymidine (AZT) and 3′-azido-2′,3′-dideoxyuridine (AZddU) in mice. Drug Metab. Dispos. 17:1989;590-594.
55. Gallo J.M., Sanzgiri Y., Howerth E.W., et al. Serum, cerebrospinal fluid, and brain concentrations of a new zidovudine formulation following chronic administration via an implantable pump in dogs. J. Pharm. Sci. 81:1992;11-15.
56. Galinsky R.E., Hoesterey B.L., Anderson B.D. Brain and cerebrospinal fluid uptake of zidovudine (AZT) in rats after intravenous injection. Life Sci. 47:1990;781-788.
57. Masereeuw R., Jaehde U., Langemeijer M.W.E., deBoer A.G., Breimer D.D. In vitro and in vivo transport of zidovudine (AZT) across the blood-brain barrier and the effect of transport inhibitors. Pharm. Res. 11:1994;324-330.
58. Stahle L., Guzenda E., Ljungdahl-Stahle E. Pharmacokinetics and extracellular distribution to blood, brain, and muscle of alovudine (3′-fluorothymidine) and zidovudine in the rat studied by microdialysis. J. Acquir. Immune Defic. Syndr. 6:1993;435-439.
59. Dykstra K.H., Arya A., Arriola D.M., Bungay P.M., Morrison P.F., Dedrick R.L. Microdialysis study of zidovudine (AZT) transport in rat brain. J. Pharmacol. Exp. Ther. 267:1993;1227-1236.
60. Sawchuk R.J., Hedaya M.A. Modeling the enhanced uptake of zidovudine (AZT) into cerebrospinal fluid. 1. Effect of probenecid. Pharm. Res. 7:1990;332-338.
61. Hedaya M.A., Sawchuk R.J. Effect of probenecid on the renal and nonrenal clearances of zidovudine and its distribution into cerebrospinal fluid in the rabbit. J. Pharm. Sci. 78:1989;716-722.
62. Wong S.L., vanBelle K., Sawchuk R.J. Distributional transport kinetics of zidovudine between plasma and brain extracellular fluid/cerebrospinal fluid in the rabbit: Investigation of the inhibitory effect of probenecid utilizing microdialysis. J. Pharmacol. Exp. Ther. 264:1993;899-909.
63. Wang Y., Wong S.L., Sawchuk R.J. Microdialysis calibration using retrodialysis and zero-net flux: application to a study of the distribution of zidovudine to rabbit cerebrospinal fluid and thalamus. Pharm. Res. 10:1993;1411-1419.
64. Wang Y., Sawchuk R.J. Zidovudine transport in the rabbit brain during intravenous and intracerebroventricular infusion. J. Pharm. Sci. 84:1995;871-876.
65. Brewster M.E., Anderson W.R., Webb A.I., et al. Evaluation of a brain-targeting zidovudine chemical delivery system in dogs. Antimicrob. Agents Chemother. 41:1997;122-128.
66. Collins J.M., Klecker R.W., Kelley J.A., et al. Pyrimidine dideoxyribonucleosides: Selectivity of penetration into cerebrospinal fluid. J. Pharmacol. Exp. Ther. 245:1988;466-470.
67. Tuntland T., Ravasco R.J., Al-Habet S., Unadkat J.D. Efflux of zidovudine and 2′,3′-dideoxyinosine out of the cerebrospinal fluid when administered alone and in combination to Macaca nemestrina. Pharm Res. 11:1994;312-317.
68. Ljungdahl-Stahle E., Guzenda E., Bottiger D., Wahren B., Oberg B., Stahle L. Penetration of zidovudine and 3′-fluoro-3′-deoxythymidine into the brain, muscle tissue, and veins in cynomolgus monkeys: relation to antiviral action. Antimicrob. Agents Chemother. 36:1992;2418-2422.
69. Wong S.L., Wang Y., Sawchuk R.J. Analysis of zidovudine distribution to specific regions in rabbit brain using microdialysis. Pharm. Res. 9:1992;332-338.
70. Blasberg R.G., Patlak C., Fenstermacher J.D. Intrathecal chemotherapy: brain tissue profiles after ventriculocisternal perfusion. J. Pharmacol. Exp. Ther. 195:1975;73-83.
71. Terasaki T., Pardridge W.M. Restricted transport of 3′-azido-3′-deoxythymidine and dideoxynucleosides through the blood-brain barrier. J. Infect. Dis. 158:1988;630-632.
72. Brouwers P., Hendricks M., Lietzau J.A., Pluda J.M., Mitsuya H., Broder S., Yarchoan R. Effect of combination therapy with zidovudine and didanosine on neuropyschological functioning in patients with symptomatic HIV disease: a comparison of simultaneous and alternating regimens. AIDS. 11:1997;59-66.
73. Gisslen M., Norkrans G., Svennerholm B., Hagberg L. The effect of human immunodeficiency virus type 1 RNA levels in cerebrospinal fluid after initiation of zidovudine or didanosine. J. Infect. Dis. 175:1997;434-437.
74. Bell J.E., Donaldson Y.K., Lowrie S., et al. Influence of risk group and zidovudine therapy on the development of HIV encephalitis and cognitive impairment in AIDS patients. AIDS. 10:1996;493-499.
75. Mahlen J., Dunlop O., Liestol K., Dobloug J.H., Goplen A.K., Torvik A. Changing incidence of HIV-induced brain lesions in Oslo, 1983-1994: effects of zidovudine treatment. AIDS. 9:1995;1165-1169.
76. Tozzi V., Narciso P., Galgani S., et al. Effects of zidovudine in 30 patients with mild to end-stage AIDS dementia complex. AIDS. 7:1993;683-692.
77. Spector R. Thymidine transport in the central nervous system. J. Neurochem. 35:1980;1092-1098.
78. Spector R., Berlinger W.G. Localization and mechanism of thymidine transport in the central nervous system. J. Neurochem. 39:1982;837-841.
79. Cornford E.M., Oldendorf W.H. Independent blood-brain barrier transport systems for nucleic acid precursors. Biochim. Biophys. Acta. 394:1975;211-219.
80. Wu X., Yuan G., Brett C.M., Hui A.C., Giacomini K.M. Sodium-dependent nucleoside transport in choroid plexus from rabbit: evidence for a single transporter for purine and pyrimidine nucleosides. J. Biol. Chem. 267:1992;8813-8818.
81. Thomas S., Segal M.B. The passage of azidodeoxythymidine into and within the central nervous system: does it follow the parent compound, thymidine? J. Pharmacol. Exp. Ther. 281:1997;1211-1218.
82. Takasawa K., Terasaki T., Suzuki H., Sugiyama Y. In vivo evidence for carrier-mediated efflux transport of 3′-azido-3′-deoxythymidine and 2′,3′-dideoxyionsine across the blood-brain barrier via a probenecid-sensitive transport system. J. Pharmacol. Exp. Ther. 281:1997;369-375.
83. Takasawa K., Terasaki T., Suzuki H., Ooie T., Sugiyama Y. Distributed model analysis of 3′-azido-3′-deoxythymidine and 2′,3′-dideoxyionsine distribution in brain tissue and cerebrospinal fluid. J. Pharmacol. Exp. Ther. 282:1997;1509-1517.
84. Wang Y., Wei Y., Sawchuk R.J. Zidovudine transport within the rabbit brain during intracerebroventricular administration and the effect of probenecid. J. Pharm. Sci. 86:1997;1484-1490.
85. Collins J.M., Dedrick R.J. Distributed model for drug delivery to CSF and brain tissue. Am. J. Physiol. 245:1983;R303-R310.
86. Brewster M.E., Anderson W.R., Bodor N. Brain, blood, and cerebrospinal fluid distribution of a zidovudine chemical delivery system in rabbits. J. Pharm. Sci. 80:1991;843-846.
87. Brewster M.E., Anderson W.R., Helton D.O., Bodor N., Pop E. Dose-dependent brain delivery of zidovudine through the use of a zidovudine chemical delivery system. Pharm. Res. 12:1995;796-798.
88. Mizrachi Y., Rubinstein A., Harish Z., Biegon A., Anderson W.R., Brewster M.E. Improved brain delivery and in vitro activity of zidovudine through the use of a redox chemical delivery system. AIDS. 9:1995;153-158.
89. Brewster M.E., Pop E., Braunstein A.J., et al. The effects of dihydronicotinate N-substitution on the brain-targeting efficacy of a zidovudine chemical delivery system. Pharm. Res. 10:1993;1356-1362.
90. Chu C.K., Bhadti V.S., Doshi K.J., et al. Brain targeting of anti-HIV nucleosides: synthesis and in vitro and in vivo studies of dihydropyridine derivatives of 3′-azido-2′,3′-dideoxyuridine and 3′-azido-3′-deoxythymidine. J. Med. Chem. 33:1990;2188-2192.
91. Little R., Bailey D., Brewster M.E., et al. Improved delivery through biological membranes. XXXIII. Brain enhanced delivery of azidothymidine (AZT). J. Biopharm. Sci. 1:1990;1-18.
92. Torrence P.F., Kinjo J., Lesiak K., Balzarini J., Clercq E.D. AIDS dementia; synthesis and properties of a derivative of 3′-azido-3′-deoxythymidine (AZT) that may become 'locked' in the central nervous system. FEBS Lett. 234:1988;135-140.
93. Namane A., Gouyette C., Fillion M.-P., Fillion G., Huynh-Dinh T. Improved brain delivery of AZT using a glycosyl phosphotriester prodrug. J. Med. Chem. 35:1992;3039-3044.
94. Lupia R.H., Ferencz N., Lertora J.J.L., Aggarwal S.K., George W.J., Agrawal K.C. Comparative pharmacokinetics of two prodrugs of zidovudine in rabbits: enhanced levels of zidovudine in brain tissue. Antimicrob. Agents Chemother. 37:1993;818-824.
95. Tsuzuki N., Hama T., Kawada M., et al. Adamantane as a brain-directed drug carrier for poorly absorbed drug. 2. AZT derivatives conjugated with the 1-adamantane moiety. J. Pharm. Sci. 83:1994;481-484.
96. Wang L., Morin K.W., Kumar R., et al. In vivo biodistribution, pharmacokinetic parameters, and brain uptake of 5-halo-6-methoxy(or ethoxy)-5,6-dihydro-3′-azido-3′-deoxythymidine diastereomers as potential prodrugs of 3′-azido-3′-deoxythymidine. J. Med. Chem. 39:1996;826-833.
97. Tadayoni B.M., Friden P.M., Walus L.R., Musso G.F. Synthesis, in vitro kinetics, and in vivo studies on protein conjugates of AZT: evaluation as a transport system to increase brain delivery. Bioconjugate Chem. 4:1993;139-145.
98. Bodor N., Farag H., Brewster M.E. Site-specific sustained release of drug to the brain. Science. 214:1981;1370-1372.
99. Petty B.G., Kornhauser D.M., Lietman P.S. Zidovudine with probenecid: a warning. Lancet. 335:1990;1044-1045.
100. Morse G.D., Lechner J.L., Santora J.A., Rozek S.L. Zidovudine update: 1990. DICP. 24:1990;754-760.
101. deMiranda P., Good S.S., Yarchoan R., et al. Alteration of zidovudine pharmacokinetics by probenecid in patients with AIDS or AIDS-related complex. Clin. Pharmacol. Ther. 46:1989;494-500.
102. Hedaya M.A., Elmquist W.F., Sawchuk R.J. Probenecid inhibits the metabolic and renal clearances of zidovudine (AZT) in human volunteers. Pharm. Res. 7:1990;411-417.
103. Hartman N.R., Yarchoan R., Pluda J.M., et al. Pharmacokinetics of 2′,3′-dideoxyadenosine and 2′,3′-didoxyinosine in patients with severe human immunodeficiency virus infection. Clin. Pharmacol. Ther. 47:1990;647-654.
104. Burger D.M., Kraayeveld C.L., Meenhorst P.L., Mulder J.W., Hoeteimans R.M.W., Koks C.H.W., Beijnen J.H. Study on didanosine concentrations in cerebrospinal fluid: implication for the treatment and prevention of AIDS dementia complex. Pharmacy World and Science. 17:1995;218-221.
105. Balis F.M., Pizzo P.A., Butler K.M., et al. Clinical pharmacology of 2′,3′-dideoxyinosine in human immunodeficiency virus-infected children. J. Infect. Dis. 165:1992;99-104.
106. Anderson B.D., Hoesterey B.L., Baker D.C., Galinsky R.E. Uptake kinetics of 2′,3′-dideoxyinosine into brain and cerebrospinal fluid of rats: intravenous infusion studies. J. Pharmacol. Exp. Ther. 253:1990;113-118.
107. Hoesterey B.L., Galinsky R.E., Anderson B.D. Dose depedence in the plasma pharmacokinetics and uptake kinetics of 2′,3′-dideoxyinosine into brain and cerebrospinal fluid of rats. Drug Metab. Dispos. 19:1991;907-912.
108. Galinsky R.E., Flaharty K.K., Hoesterey B.L., Anderson B.D. Probenecid enhances central nervous system uptake of 2′,3′-dideoxyinosine by inhibiting cerebrospinal fluid efflux. J. Pharmacol. Exp. Ther. 257:1991;972-978.
109. Singhal D., Morgan M.E., Anderson B.D. Role of brain tissue localized purine metabolizing enzymes in the central nervous system delivery of anti-HIV agents 2′-β-fluoro-2′,3′-dideoxyinosine and 2′-β-fluoro-2′,3′-dideoxyadenosine in rats. Pharm. Res. 14:1997;786-792.
110. Morgan M.E., Chi S.-C., Murakami K., Mitsuya H., Anderson B.D. Central nervous system targeting of 2′,3′-dideoxyinosine via adenosine deaminase-activated 6-halo-dideoxypurine prodrugs. Antimicrob. Agents Chemother. 36:1992;2156-2165.
111. Kang H.-J.K., Wientjes M.G., Au J.L.-S. Tissue pharmacokinetics of 2′,3′-dideoxyinosine in rats. Biochem. Pharmacol. 48:1994;2109-2116.
112. Wientjes M.G., Placke M.E., Chang M.J.-W., Page J.G., Kluwe W.M., Tomaszewski J.E. Pharmacokinetics of 2′,3′-dideoxyinosine in dogs. Invest. New Drugs. 9:1991;159-168.
113. Hawkins M.E., Mitsuya H., McCully C.M., et al. Pharmacokinetics of dideoxypurine nucleoside analogs in plasma and cerebrospinal fluid of rhesus monkeys. Antimicrob. Agents Chemother. 39:1995;1259-1264.
114. Ahluwalia G., Cooney D.A., Mitsuya H., et al. Initial studies of the cellular pharmacology of 2′,3′-dideoxyinosine, an inhibitor of HIV infectivity. Biochem. Pharmacol. 36:1987;3797-3800.
115. Ohno K., Pettigrew K.D., Rapoport S.I. Lower limits of cerebrovascular permeability to nonelectrolytes in the conscious rats. Am. J. Physiol. 235:1978;H299-H307.
116. Plagemann P.G., Woffendin C. Permeation and salvage of dideoxyadensoine in mammalian cells. Mol. Pharmacol. 36:1989;185-192.
117. Kalaria R.N., Harik S.I. Nucleoside transporter of cerebral microvessels and choroid plexus. J. Neurochem. 47:1986;1849-1856.
118. Johnson M.D., Anderson B.D. Localization of purine metabolizing enzymes in bovine brain microvessel endothelial cells: an enzymatic blood-brain barrier for dideoxynucleosides? Pharm. Res. 13:1996;1881-1886.
119. Anderson B.D., Hoesterey B.L., Baker D.C., Galinsky R.E. Kinetics of ddI in plasma, brain, and CSF of rats after administration of ddI and an ester prodrug of ddI. Ann. N.Y. Acad. Sci. 616:1990;472-474.
120. Wen Y.-D., Remmel R.P., Pham P.T., Vince R., Zimmerman C.L. Comparative brain exposure to (-)-carbovir after (-)-carbovir or (-)-6-aminocarbovir intravenous infusion in rats. Pharm. Res. 12:1995;911-915.
121. Klecker R.W., Collins J.M., Yarchoan R.C., et al. Pharmacokinetics of 2′,3′-dideoxycytidine in patients with AIDS and related disorders. J. Clin. Pharmacol. 28:1988;837-842.
122. Yarchoan R., Perno C.F., Thomas R.V., et al. Phase I studies of 2′,3′-dideoxycytidine in severe human immunodeficiency virus infection as a single agent and alternating with zidovudine (AZT). Lancet. 1:1988;76-81.
123. Torrence P.F., Kinjo J., Khamnei S., Greig N.H. Synthesis and pharmacokinetics of a dihydropyridine chemical delivery system for the anti-immunodeficiency virus agent dideoxycytidine. J. Med. Chem. 36:1993;529-537.
124. Kelly J.A., Litterst C.L., Roth J.S., et al. The disposition and metabolism of 2′,3′-dideoxycytidine, an in vitro inhibitor of human T-lymphotrophic virus type III infectivity, in mice and monkeys. Drug Metab. Dispos. 15:1987;595-601.
125. Plagemann P.G., Woffendin C. Dideoxycytidine permeation and salvage by mouse leukemia cells and human erythrocytes. Biochem. Pharmacol. 38:1989;3469-3475.
126. Dudley M.N., Graham K.K., Kaul S., et al. Pharmacokinetics of stavudine in patients with AIDS or AIDS-related complex. J. Infect. Dis. 166:1992;480-485.
127. Kline M.W., Dunkle L.M., Church J.A., et al. A phase I/II evaluation of stavudine (d4T) in children with human immunodeficiency virus infection. Pediatrics. 96:1995;247-252.
128. Haworth S., Christofalo B., Anderson R.D., Dunkle L.M. A single-dose study to assess the penetration of stavudine into human cerebrospinal fluid in adults. AIDS Res. Hum. Retroviruses. 17:1998;235-238.
129. Russell J.W., Whiterock V.J., Marrero D., Klunk L.J. Pharmacokinetics of a new anti-HIV agent: 2′,3′-dideoxy-2′,3′-didehydrothymidine (d4T). Nucleosides Nucleotides. 8:1989;845-848.
130. Russell J.W., Whiterock V.J., Marrero D., Klunk L.J. Disposition in animals of a new anti-HIV agent: 2′,3′-didehydro-3′-deoxythymidine. Drug Metab. Dispos. 18:1990;153-157.
131. Schinazi R.F., Boudinot F.D., Doshi K.J., McClure H.M. Pharmacokinetics of 3′-fluoro-3′-deoxythymidine and 3′-deoxy-2′,3′-didehydrothymidine in rhesus monkeys. Antimicrob. Agents Chemother. 34:1990;1214-1219.
132. Odinecs A., Nosbisch C., Keller R.D., Baughman W.L., Unadka J.D. In vivo maternal-fetal pharmacokinetics of stavudine (2′,3′-didehydro-3′-deoxythymidine) in pigtailed macaques (Macaca nemestrina). Antimicrob. Agents Chemother. 40:1996;196-202.
133. Bawdon R.E., Kaul S., Sobhi S. The ex vivo transfer of the anti-HIV nucleoside compound d4T in the human placenta. Gynecol. Obstet. Invest. 38:1994;1-4.
134. August E.M., Birks E.M., Prusoff W.H. 3′-deoxythymidin-2′-ene permeation of human lymphocyte H9 cells by nonfacilitated diffusion. Mol. Pharmacol. 39:1990;246-249.
135. Boudinot F.D., Smith S.G., Funderburg E.D., Schinazi R.F. Pharmacokinetics of 3′-fluoro-3′-deoxythymidine and 3′-deoxy-2′,3′-didehydrothymidine in rats. Antimicrob. Agents Chemother. 35:1991;747-749.
136. Palomino E., Kessel D., Horwitz J.P. A dihydropyridine carrier system for sustained delivery of 2′,3′-dideoxynucleosides to the brain. Journal of Medicinal Chemistry. 32:1989;622-625.
137. vanLeeuwen R., Katlama C., Kitchen V., et al. Evaluation of safety and efficacy of 3TC (lamivudine) in patients with asymptomatic or mildly symptomatic human immunodeficiency virus infection: a phase I/II study. J. Infect. Dis. 171:1995;1166-1171.
138. Blaney S.M., Daniel M.J., Harker A.J., Godwin K., Balis F.M. Pharmacokinetic of lamivudine and BCH-189 in plasma and cerebrospinal fluid of nonhuman primates. Antimicrob. Agents Chemother. 39:1995;2779-2782.
139. Keppler D., Leier I., Jeditschky G., Konig J. ATP-dependent transport of glutathione S-conjugate by the multidrug resistance protein MRP and its apical isoform MRP2. Chem. Biol. Interact. 111-112:1998;153-161.
140. Huai-Yun H., Secrest D.T., Mark K.S., et al. Expression of multidrug resistance-associated protein (MRP) in brain microvessel endothelial cells. Biochem. Biophys. Res. Commun. 243:1998;816-820.
141. Roelofsen H., Muller M., Jansen P.L.M. Regulation of organic anion transport in the liver. Yale J. Biol. Med. 70:1997;435-445.
142. Kool M., de Hass M., Scheffer G.L., et al. Analysis of expression of cMOAT (MRP2), MRP3, MRP4, and MRP5, homologues of the multidrug resistance-associated protein gene (MRP1), in human cancer cell lines. Cancer Res. 57:1997;3537-3547.
143. Zaman G.J.R., Flens M.J., vanLeusden M.E., et al. The human multidrug resistance-associated protein MRP is a plasma membrane drug-efflux pump. Proc. Natl. Acad. Sci. USA. 91:1994;8822-8826.
144. Kusuhara H., Suzuki H., Naito M., Tsuruo T., Sugiyama Y. Characterization of efflux transport of organic anions in a mouse brain capillary endothelial cell line. J. Pharmacol. Exp. Ther. 285:1998;1260-1265.
145. Miller D.W., Maier J.L. Evidence for the existence of separate drug efflux system corresponding to P-glycoprotein (P-gp) and multidrug resistance-associated protein (MRP) in brain microvessel endothelial cells. Pharm. Res. 12:1995;S381.
146. Lee K., Belinsky M.G., Bell D.W., Testa J.R., Kruh G.D. Isolation of MOAT-B, a widely expressed multidrug resistance-associated protein/canalicular multispecific organic anion transporter-related transporter. Cancer Res. 58:1998;2741-2747.
147. Power C., Kong P.A., Crawford T.O., et al. Cerebral white matter changes in acquired immunodeficiency syndrome dementia: alterations of the blood-brain barrier. Ann. Neurol. 34:1993;339-350.
148. Petito C.K., Cash K.S. Blood-brain barrier abnormalities in the acquired immunodeficiency syndrome: immunohistochemical localization of serum proteins in postmortem brain. Ann. Neurol. 32:1992;658-666.
149. Rhodes R.H. Evidence of serum-protein leakage across the blood-brain barrier in the acquired immunodeficiency syndrome. J. Neuropathol. Exp. Neurol. 50:1991;171-183.
150. Brew B.J., Bhalla R.B., Paul M., et al. Cerebrospinal fluid beta 2-microglobulin in patients with AIDS dementia complex; an expanded series including response to zidovudine treatment. AIDS. 6:1992;461-465.
151. Hagberg L., Norkrans G., Gisslen M., Wachter H., Fuchs D., Svennerholm B. Intrathecal immunoactivation in patients with HIV-1 infection is reduced by zidovudine but not by didanosine. Scand. J. Infect. Dis. 28:1996;329-333.
152. Rutschmann O., Hirschel B. Antiretroviral therapy: a guide to the most important trials. Schweiz. Med. Wochenschr. 127:1997;436-443.
153. Glynn S.L., Yazdanian M. In vitro blood-brain barrier permeability of nevirapine compared to other HIV antiretroviral agents. Journal of Pharmaceutical Sciences. 87:1998;306-310.
154. Murphy R., Montaner J. Nevirapine: a review of its development, pharmacological profile and potential clinical use. Exp. Opin. Invest. Drugs. 5:1996;1183-1199.
155. Chang M., Sood V.K., Wilson G.J., et al. Metabolism of the HIV-1 reverse transcriptase inhibitor delavirdine in mice. Drug Metab Dispos. 25:1997;828-839.
156. Brew B.J., Dunbar N., Druett J.-A., Freund J., Ward P. Pilot study of the efficacy of atevirdine in the treatment of AIDS dementia complex. AIDS. 10:1996;1357-1360.
157. Lin J.H., Chiba M., Balani S.K., et al. Species differences in the pharmacokinetics and metabolism of indinavir, a potent human immunodeficiency virus protease inhibitor. Drug Metab. Dispos. 24:1996;1111-1120.
158. Kakuda T.N., Struble K.A., Piscitelli S.C. Protease inhibitors for the treatment of human immunodeficiency virus dysfunction. Am. J. Health-Syst. Pharm. 55:1998;233-254.
159. Kim R.B., Fromm M.F., Wandel C., et al. The drug transporter P-glycoprotein limits oral absorption and brain entry of HIV-1 protease inhibitors. J. Clin. Invest. 101:1998;289-294.
160. Filippi C.G., Sze G., Farber S.J., Shahmanesh M., Selwyn P.A. Regression of HIV encephalopathy and basal ganglia signal intensity abnormality at MR imaging in patients with AIDS after the initiation of protease inhibitor therapy. Radiology. 206:1998;491-498.
161. Vertex announces HIV protease inhibitor amprenavir shown in clinical trials to cross the blood-brain barrier and penetrate to key viral reservoir. PR News Wire, June 5th, 1998.